{
    "Trade/Device Name(s)": [
        "Accuwell 17-a-Hydroxyprogesterone (OHP) enzyme immunoassay (EIA)",
        "Accuwell 17-a-Hydroxyprogesterone Neonatal Screening Enzyme Immunoassay"
    ],
    "Submitter Information": "Genesis Northwest (dba) Neo-Genesis",
    "510(k) Number": "K060452",
    "Predicate Device Reference 510(k) Number(s)": [
        "K042425"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "JLX"
    ],
    "Summary Letter Date": "January 31, 2007",
    "Summary Letter Received Date": "February 2, 2007",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1395"
    ],
    "Regulation Name(s)": [
        "17-Hydroxyprogesterone test system"
    ],
    "Analyte Class(es)": [
        "endocrine",
        "chemistry"
    ],
    "Analyte(s)": [
        "17-alpha-Hydroxyprogesterone"
    ],
    "Specimen Type(s)": [
        "Neonatal blood (dried blood spots)"
    ],
    "Specimen Container(s)": [
        "Whatman 903 specimen collection paper"
    ],
    "Instrument(s)/Platform(s)": [
        "96-well microplate",
        "Microplate absorbance reader"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)",
        "Competitive solid phase assay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Accuwell 17-a-Hydroxyprogesterone neonatal screening enzyme immunoassay kit for quantitative measurement in newborn dried blood spots",
    "Indications for Use Summary": "Quantitative measurement of 17-alpha-Hydroxyprogesterone in neonatal blood spots for screening newborns for classical congenital adrenal hyperplasia (CAH)",
    "fda_folder": "Clinical Chemistry"
}